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Abstract: Angiotensin-converting enzyme inhibitors (ACEI) and statins are widely used in patients
with coronary artery disease (CAD). Our aim was to compare changes in glomerular filtration rate
(GFR) over time in subjects with stable CAD according to atorvastatin dose and concomitant use
of ACEI. We studied 78 men with stable CAD referred for an elective coronary angiography who
attained the then-current guideline-recommended target level of low-density lipoproteins (LDL)
cholesterol below 2.5 mmol/L in a routine fasting lipid panel on admission and were receiving
atorvastatin at a daily dose of 10–40 mg for ě3 months preceding the index hospitalization. Due to
an observational study design, atorvastatin dosage was not intentionally modified for other reasons.
GFR was estimated during index hospitalization and at about one year after discharge from our center.
Irrespective of ACEI use, a prevention of kidney function loss was observed only in those treated
with the highest atorvastatin dose. In 38 subjects on ACEI, both of the higher atorvastatin doses were
associated with increasing beneficial effects on GFR changes (mean ˘ SEM: ´4.2 ˘ 2.4, 1.1 ˘ 1.6,
5.2˘ 2.4 mL/min per 1.73 m2 for the 10-mg, 20-mg and 40-mg atorvastatin group, respectively, p = 0.02
by ANOVA; Spearman’s rho = 0.50, p = 0.001 for trend). In sharp contrast, in 40 patients without
ACEI, no significant trend effect was observed across increasing atorvastatin dosage (respective GFR
changes: ´1.3 ˘ 1.0, ´4.7 ˘ 2.1, 4.8 ˘ 3.6 mL/min per 1.73 m2, p = 0.02 by ANOVA; rho = 0.08,
p = 0.6 for trend). The results were substantially unchanged after adjustment for baseline GFR or
time-dependent variations of LDL cholesterol. Thus, concomitant ACEI use appears to facilitate the
ability of increasing atorvastatin doses to beneficially modulate time-dependent changes in GFR in
men with stable CAD.
Keywords: angiotensin-converting enzyme inhibitors; coronary artery disease; glomerular filtration rate;
renal function decline; statins
1. Introduction
As early as 2001, a meta-analysis of randomized controlled studies by Fried et al. [1] suggested
the ability of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins),
to slow down renal function decline in patients with renal diseases. Five years later, a meta-analysis by
Sandhu et al. [2] also identified renal benefits of statins, including a small yet significant reduction in the
rate of kidney function loss, especially in populations with atherosclerotic cardiovascular (CV) disease.
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However, according to some recent meta-analyses, despite a lower risk of CV events in predialysis
chronic kidney disease (CKD) subjects on statins, renoprotective statin effects were unclear with a
significant heterogeneity across the included CKD studies [3,4]. Nikolic et al. [5] have recently reported
a beneficial effect of statins on glomerular filtration rate (GFR) changes only for between one and three
years of statin therapy in CKD. In contrast to these inconsistent results, a meta-analysis of controlled
studies in CKD patients treated with atorvastatin revealed an evidence of the atorvastatin-induced
renoprotection that was independent of follow-up duration and persisted after exclusion of any
single trial from the analysis including the largest Treating to New Targets (TNT) study [6]. These
discrepancies could be partially linked to a dosage-dependence of renal benefits of statins, recently
demonstrated irrespective of the presence of CKD [7,8].
Angiotensin-converting enzyme inhibitors (ACEI) are recommended in CKD due to their
well-recognized ability to reduce proteinuria and delay renal function decline. In addition, ACEI
should be considered for CV event prevention even in patients with stable angina and without
coexistent strong indications for this class of drugs, i.e., left ventricular systolic dysfunction, diabetes
or hypertension [9,10]. However, ACEI were used by only about 28% of the subjects participating
in the TNT trial that demonstrated greater improvements in GFR over five years in patients with
stable coronary artery disease (CAD) randomized to 80-mg atorvastatin vs. 10-mg atorvastatin [11].
Of note, in the Protection Against Nephropathy in Diabetes with Atorvastatin (PANDA) trial two-year
GFR changes were similar in type 2 diabetics with early nephropathy allocated 80-mg and 10-mg
atorvastatin, all of whom were receiving either ACEI or angiotensin II type 1 receptor blockers
(ARB) [12].
Therefore, we hypothesized that dose-dependent effects of atorvastatin on renal function might
be modified by ACEI use. Thus, the aim of our observational study was to compare GFR changes over
time in men with stable CAD according to the dose of atorvastatin and concomitant usage of ACEI.
2. Results
Clinical and biochemical characteristics of our patients according to atorvastatin dose have been
shown in Table 1.
Table 1. Patients’ characteristics according to atorvastatin dose.
Characteristic
Atorvastatin Daily Dose p-Value
10-mg, n = 29 20-mg, n = 24 40-mg, n = 25
Age (years) 56 ˘ 10 57 ˘ 9 55 ˘ 10 NS
Hypertension, n (%) 25 (86%) 19 (79%) 20 (80%) NS
Diabetes, n (%) 9 (31%) 6 (25%) 5 (20%) NS
Left ventricular ejection fraction (%) 68 ˘ 6 70 ˘ 7 70 ˘ 6 NS
Body-mass index (kg/m2) 27.4 ˘ 3.4 26.8 ˘ 2.9 27.0 ˘ 3.1 NS
Mean blood pressure (mmHg) 99 ˘ 9 97 ˘ 9 96 ˘ 8 NS
LDL cholesterol (mmol/L) 2.1 ˘ 0.3 2.0 ˘ 0.4 2.2 ˘ 0.3 NS
HDL cholesterol (mmol/L) 0.9 ˘ 0.3 1.1 ˘ 0.3 1.0 ˘ 0.3 NS
Triglycerides (mmol/L) 1.7 ˘ 0.7 1.6 ˘ 0.6 1.5 ˘ 0.6 NS
Data are shown as mean ˘ SD; p-values by one-way ANOVA or chi-squared test. HDL: high-density lipoproteins;
LDL: low-density lipoproteins; NS: non-significant.
Baseline GFR did not differ significantly across subgroups of patients treated with different
atorvastatin doses (mean ˘ SEM: 52.4 ˘ 2.6, 59.3 ˘ 3.5, 62.5 ˘ 3.1 mL/min per 1.73 m2 for the 10-mg,
20-mg and 40-mg atorvastatin group, respectively; p = 0.4 by one-way analysis of variance [ANOVA]).
Out of 78 study subjects, 40 patients were receiving no ACEI, largely due to a history of adverse
renal side-effects, which resulted in a significantly higher GFR in those with ACEI (69.5 ˘ 2.7 vs.
43.5 ˘ 2.0 mL/min per 1.73 m2, p < 0.001). Among ACEI users, study subjects were treated mainly
with ramipril (2.5–10 mg daily), perindopril (2–8 mg daily) or enalapril (5–30 mg daily).
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Pooling all study subjects together, we found a significant effect of atorvastatin dose on changes in
GFR, predominantly secondary to a GFR increase in those receiving 40-mg atorvastatin (GFR change:
´2.6 ˘ 1.2, ´2.1 ˘ 1.5, 5.0 ˘ 2.0 mL/min per 1.73 m2 for the 10-mg, 20-mg and 40-mg atorvastatin
group, respectively, p = 0.001 by ANOVA; p = 0.002 for trend) (Figure 1).
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Figure 1. Changes of glomerular filtration rate (GFR) over 1 year (mean ˘ SEM) according to
atorvastatin dosage.
ACEI use was ot significantly associated with GFR changes (0.9 ˘ 1.4 vs. ´0.5 ˘ 1.3 mL/min
per 1.73 m2 for patients with and without ACEI, respectively, p = 0.6 by ANOVA).
Changes of GFR over one year did not correlate to any of the baseline clinical and biochemical
characteristics (p > 0.1) or longitudinal changes in low-density lipoproteins (LDL) cholesterol (p = 0.4)
and mean blood pressure (p = 0.5).
Irrespective of ACEI use, a prevention of kidney function loss was observed only in those treated
with the highest atorvastatin dose (Table 2; Figure 2). In subjects on ACEI (n = 38), both of the higher
atorvas atin doses were accompanied by increasing benefi ial effects on time-dependent changes in
GFR (p = 0.02 by ANOVA; rho = 0.50, p = 0.001 for trend) (T ble 2; Figur 2). In sharp co trast, in patients
without ACEI (n = 40), no significant trend effect was observed (p = 0.02 by ANOVA; rho = 0.08, p = 0.6
for trend) (Table 2; Figure 2). With regard to the strength of these trend effects on longitudinal
GFR changes across increasing atorvastatin dosage, a positive association in subjects on ACEI
(rho = 0.50) differed significantly (p = 0.045) from the lack of respective relationship (rho = 0.08)
in patients without ACEI.
Table 2. Glomerular filtration rate (GFR) by atorvastatin dose according to the use of angiotensin-converting
enzyme inhibitors (ACEI).
GFR (mL/min per
1.73 m2)
Atorvastatin Daily Dose p-Value by
ANOVA
p-Value for
Trend10-mg 20-mg 40-mg
Patients on ACEI (n = 38)
n = 13 n = 11 n = 14
Baseline 65.9 ˘ 4.8 74.7 ˘ 6.2 69.0 ˘ 4.0 NS NS
Change over 1 year ´4.2 ˘ 2 4 1.1 ˘ 1.6 5 2 ˘ 2.4 * 0.02 0.001
Patients without ACEI (n = 40)
n = 16 n = 13 n = 11
Baseline 41.4 ˘ 4.5 49.3 ˘ 5.3 41.3 ˘ 4.3 NS NS
Change over 1 year ´1.3 ˘ 1.0 ´4.7 ˘ 2.1 4.8 ˘ 3.6 † 0.02 NS
Data are shown as mean ˘ SEM; p-values by one-way ANOVA. * p = 0.01 vs. the 10-mg group; † p = 0.02 vs. the
20-mg group by Tukey’s test; NS: non-significant.
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Figure 2. Changes of glomerular filtration rate (GFR) over one year (mean ˘ SEM) by atorvastatin
dosage stratified by the use of angiotensin-converting enzyme inhibitors (ACEI).
By multivariate analysis, a change in GFR was positively related to the treatment with 40-mg
atorvastatin. In addition, we found a significant interaction between ACEI use and the therapy with
20-mg atorvastatin (Table 3). Accordingly, in patients with ACEI we observed a higher GFR change
in the 20-mg atorvastatin group compared to the 10-mg atorvastatin group, whereas in those not
receiving ACEI an increase in GFR was found exclusively for the 40-mg group (Figure 2). The results
were substantially unchanged after inclusion of baseline GFR or time-dependent variations of LDL
cholesterol and mean blood pressure into the model.
Table 3. Multiple linear regression analysis of predictors a change in GFR over 1 year.
Predictor
Regression Coefficient p-Value
Mean ˘ SEM 95% CI
Atorvastatin daily dose
40-mg vs. 10-mg 3.9 ˘ 1.1 1.8–6.0 <0.001
20-mg vs. 10-mg 0.5 ˘ 1. ´1.7–2.7 0.7
Treatment with ACEI (yes vs. no) 1.5 ˘ 1.2 ´0.7–3.8 0.2
Interactions of ACEI use and atorvastatin dose
ACEI use and 20-mg atorvastatin 2.3 ˘ 1.1 0.1–4.5 0.04
ACEI use and 40-mg atorvastatin 0.8 ˘ 1.1 ´1.3–2.9 0.5
R2 for the whole model: 0.22; p = 0.003.
3. Discussion
Our salient finding was the ability of ACEI use to modulate the relation between atorvastatin
dose of 10–40 mg daily and GFR changes over a mean follow-up of 12 months in men with stable
CAD. In the study subjects on ACEI, the use of atorvastatin was associated with increasing beneficial
effects on kidney function beginning from an atorvastatin dose of 20 mg, whereas in those receiving no
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ACEI, no significant trend effect was found. Additionally, time-dependent changes in GFR appeared
independent of concomitant longitudinal variations of LDL cholesterol or blood pressure.
3.1. Mechanistic Considerations
Our findings may be indicative of the relevance of cholesterol-independent pleiotropic statin
actions for the renal benefit achieved with atorvastatin. Admittedly, cholesterol lowering through
HMG-CoA reductase inhibition is the principal mechanism of statin actions; however, because
cholesterol levels were similar in patients treated with three atorvastatin doses, a hypothetical role of
cholesterol-independent pathways can be hypothesized. Beyond cholesterol reduction, pleiotropic
statin effects include attenuation of endothelial dysfunction as well as anti-inflammatory, antioxidant,
antiproliferative, antifibrotic and sympatholytic activity [5,13,14], all of which were also shown for
ACEI [15]. Moreover, adding a statin to ACEI ameliorated renal function, reduced proteinuria and
prevented glomerulosclerosis, tubular damage and interstitial fibrosis in several experimental models
of kidney disease [16–19]. Additionally, statins are able to down-regulate angiotensin II type 1
receptors [20,21], whose density is known to increase in patients on ACEI. Thus, it does not seem
implausible to assume that converging intercellular pathways mediating ACEI and statin activities
could be responsible for the association of favorable GFR changes with statin therapy at a lower dose
of atorvastatin in ACEI users compared with those receiving no ACEI. This concept appears much
more likely than altered atorvastatin metabolism due to a difference in renal function according to
ACEI use because the drug is eliminated primarily in the bile and no dose adjustment is required in
CKD [22].
Admittedly, it is doubtful whether long-term effects of statin therapy on kidney structure in
animal models of CKD [16–19] could translate into measurable effects on GFR within a relatively short
follow-up in the present study. Therefore, we can hypothesize that our findings might rather be linked
to hemodynamic statin actions. This concept was also proposed by Athyros et al. [23] as an explanation
for early increase in GFR already at the sixth week of treatment with the starting atorvastatin dose of
10 mg/day in subjects with established CAD and dyslipidemia participating in the GREek Atorvastatin
and Coronary heart disease Evaluation (GREACE) study, with the greatest benefit in those with early
renal dysfunction. It is noteworthy that ACEI—shown to delay CKD progression on a long-term
basis [15]—did not independently influence GFR changes in the present study.
Statins may exert renal hemodynamics via preglomerular vasodilation [24], a likely consequence
of an increased bioavailability of nitric oxide (NO), all the more because short-term (six weeks)
treatment with rosuvastatin potentiated the dependence of renal plasma flow on NO generation
in patients with hypercholesterolemia, with a trend towards improved basal NO activity already
after three-day therapy [25]. Of note, in healthy subjects the dependence of fractional sodium
excretion on the L-arginine–NO pathway was more pronounced after five-day treatment with 80 mg
atorvastatin daily [26]. In addition, GFR improved after a four-week therapy with 40 mg simvastatin
per day in patients with autosomal dominant polycystic kidney disease, which was associated with
improved endothelium-dependent dilation in the forearm [27]. On the other hand, in subjects with
type 2 diabetes, administration of atorvastatin (10 or 80 mg/day) for 30 weeks neither improved
impaired flow-mediated dilation of the brachial artery [28] nor affected urinary markers of systemic
NO generation and oxidative stress [29] as compared to patients randomized to placebo.
Elevated bioavailability of renal NO produces not only the dilation of glomerular arterioles,
but also local NO generated in the juxtaglomerular apparatus can antagonize the angiotensin
II-dependent enhancement of vasoconstrictory responses of afferent arterioles via tubuloglomerular
feedback (TGF) [30]. In keeping with this concept, Song et al. [31] have recently demonstrated
augmented TGF responsiveness associated with increased superoxide generation and decreased
NO formation by neuronal NO synthase in the macula densa in a model of hypertension induced with
slow-pressor infusion of angiotensin II in mice. Furthermore, Park et al. [32] observed the ability
of rosuvastatin to protect against angiotensin II-induced inflammatory and profibrotic activation
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and renal injury in a transgenic model of angiotensin II-induced hypertension and target-organ
damage. Finally, atorvastatin attenuated renal oxidative stress, exerted anti-inflammatory and
antifibrotic effects, prevented glomerulosclerosis and upregulated renal endothelial NO synthase
in a rat model of salt-sensitive hypertension associated with increased angiotensin II-dependent
activation of nicotinamide adenine dinucleotide phosphate oxidases [33].
Thus, we can hypothesize that restoration of renal NO activity on statins could be especially
beneficial under ACE inhibition because it might possibly maintain an equilibrium between the
angiotensin II-mediated postglomerular vasoconstriction and the TGF-dependent preglomerular
vasoconstriction, thereby preventing excessive GFR reductions on ACEI.
3.2. Clinical Implications
Irrespective of these speculative mechanistic considerations, the results of the present study may
translate into bedside, although the study population, with a prevalence of diabetes of only 25%,
could be considered at low risk for CKD progression upon exclusion of subjects with heart failure,
left ventricular systolic dysfunction and uncontrolled hypertension. In the clinical practice, ACEI and
ARB tend to be underused in patients with increasing stages of CKD due to perceived safety concerns
about adverse renal effects of these drugs [34], which was also evident in our study group. Therefore,
subjects with CKD, who are receiving no ACEI therapy, are devoid of a valuable tool in the medical
armamentarium aimed at slowing down CKD progression, being thus more dependent on alternative
strategies to protect against GFR deterioration. Accordingly, since we were able to detect the ability
of 40-mg atorvastatin to prevent a fall of GFR over a one-year follow-up period in ACEI non-users,
higher atorvastatin doses may be a reasonable option in this clinical setting not only to attenuate the
risk of adverse CV outcome but also to prevent renal function decline.
Furthermore, the ability of statin to improve GFR appears augmented in CKD because, in the
TNT study, the mean percentage increase from baseline GFR was higher among participants with a
baseline GFR below 60 mL/min per 1.73 m2 both for the patients allocated 80-mg atorvastatin (9.9% vs.
7.6%) and in the 10-mg arm (6.6% vs. 5.2%) [11]. In addition, relative GFR improvements associated
with titrate-to-goal regimens of atorvastatin (10 to 80 mg per day) over a regimen of “usual care” were
more pronounced in individuals with established CAD and coexistent CKD compared to those with a
normal renal function in the GREACE (15% [GFR < 77 mL/min] vs. 3% [GFR > 77 mL/min]; mean
atorvastatin dose: 24 mg/day) [23] and Aggressive Lipid-Lowering Initiation Abates New Cardiac
Events (ALLIANCE) trial (4.5% [CKD] vs. 1.1% [no CKD]; mean atorvastatin dose: 40.5 mg/day) [35].
In some analogy to these reports, in the patients treated with 40-mg atorvastatin, we observed
a higher relative increase in GFR in those without ACEI (about 12%) vs. ACEI users (about 7.5%),
whereas average GFR was lower by almost 30 mL/min per 1.73 m2 in the former. However, GFR
changes according to ACEI/statin use were previously reported only in a post hoc analysis of the
GREACE study, being similar during a three-year follow-up in patients taking the combination of a
statin (mainly atorvastatin) plus an ACEI and those receiving a statin without ACEI [36]. With regard
to the TNT [11] and ALLIANCE [35] study, renal effects of atorvastatin according to the treatment with
ACEI/ARB have not been reported so far.
It needs to be acknowledged that we were not able to make comparisons with the reference to
patients without statins. However, assuming the notion of the hypothetical ACEI–statins interactions
in terms of GFR changes, the magnitude of GFR improvements over time can possibly be perceived
as a renal “mirror” of additive beneficial effects of ACEI and statins on clinical outcome, previously
demonstrated in patients with CAD [36] and recently in diabetic subjects with critical limb ischemia [37].
Moreover, the proposed concept can also indirectly imply a higher ability of lower atorvastatin doses to
produce beneficial effects on renal function in ACEI users vs. non-users, which was found in the present
study. Of note, in a placebo-controlled study, Bianchi et al. [38] observed that adding a mean dose of
15 mg of atorvastatin daily to ACEI or ARB prevented one-year renal function decline and reduced
proteinuria in patients with mild-to-moderate CKD due to idiopathic chronic glomerulonephritis.
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Unfortunately, the proportional use of ACEI and ARB was not reported by the Lipid Lowering and
Onset of Renal Disease (LORD) trial investigators who observed no statistical difference in 2.5-year GFR
changes between CKD subjects of various etiology randomized to 10-mg atorvastatin and placebo [39].
3.3. Study Limitations
First, a relatively low number of the patients and observational study design are major study
limitations and a randomized assignment of the subjects to ACEI therapy and different atorvastatin
doses would be more appropriate. However, we analyzed only patients who were already on
atorvastatin (with or without ACEI) for at least three months preceding the index hospitalization
and attained the then-current guideline-recommended target levels of LDL cholesterol in a routine
fasting lipid panel on admission; Second, we did not routinely estimate proteinuria and indices
of calcium/phosphorus metabolism, also known to affect CKD progression; Finally, because study
subjects were followed on an outpatient basis, we were able to collect exclusively a self-reported
history of medication use after discharge from our department.
4. Experimental Section
4.1. Patients
We studied men with stable CAD referred for an elective diagnostic coronary angiography who
exhibited the presence of at least one epicardial coronary narrowing of ě70% and were being treated
in accordance with current practice guidelines including aspirin and statin for ě3 preceding months.
All patients underwent a complex percutaneous coronary angioplasty in our center. As described
previously, a wide set of exclusion criteria was applied to reduce the heterogeneity of the study
population [40]. We had a priori excluded subjects with heart failure/left ventricular systolic dysfunction,
significant valvular heart disease or congenital heart disease, arterial hypertension not adequately
controlled by drugs, a history of acute coronary syndrome within the previous three months, major
surgery in the past six months, GFR >120 or <30 mL/min per 1.73 m2 of body-surface area, evidence
of abnormal liver function, contrast nephropathy during index hospitalization, relevant abnormalities
in routine blood analysis, coexistent inflammatory or malignant diseases, and chronic medication
with non-steroidal anti-inflammatory drugs or coxibs. In the present study, we analyzed only
subjects who attained the then-current guideline-recommended target level of LDL cholesterol below
2.5 mmol/L [9,10] in a routine fasting lipid panel on admission and were receiving daily atorvastatin
doses between 10 and 40 mg prior to the index hospitalization. Due to an observational study design,
the doses of atorvastatin were not intentionally modified for other reasons in the analyzed patients.
Out of 391 pre-screened patients, 282 were eliminated from the study on the basis of the above listed
inclusion and exclusion criteria.
The study was approved by the ethical committee of our institution as indicated previously [40,41]
and the patients gave informed consent.
4.2. Collection of Follow-up Data
After discharge from our department, patients underwent routine control visits in our outpatient
clinic [41] and, if deemed necessary from clinical practice indications, re-hospitalizations in our center.
In order to assess GFR changes over about a one-year follow-up, we recorded GFR—estimated by the
Chronic Kidney Disease Epidemiology Collaboration formula [42]—during the index hospitalization
and at 12 ˘ 3 months after discharge.
We excluded from the study the patients in whom atorvastatin doses were changed and/or
ACEI were permanently discontinued or introduced by an attending physician before the control
visit. Among 109 eligible patients who were followed, 31 were eliminated from the final analysis
because of a modification of the therapeutic regimen with regard to atorvastatin/ACEI after the index
hospitalization, or due to loss to follow-up.
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4.3. Statistical Analysis
Data are presented as means and SD or SEM for continuous variables or n (%) for categorical
characteristics. In order to check univariate effects of atorvastatin dose and ACEI use on changes in
GFR, ANOVA was applied with either drug dosage or ACEI therapy as a categorical predictor. Post hoc
comparisons were done by Tukey’s test. The ANOVA assumptions, i.e., the accordance with a Gaussian
distribution and uniformity of variance were tested by the Kolmogorov–Smirnov and Levene test,
respectively. Pearson’s correlation coefficients (r) were computed to assess univariate associations
between, on the one side, changes in GFR, and on the other side, baseline clinical and biochemical
characteristics as well as time-dependent changes of LDL cholesterol and mean blood pressure.
For GFR changes over time, testing for trend across increasing doses of atorvastatin was performed
with Spearman’s rank-order correlation coefficients (rho) in the study subjects stratified according to
ACEI use. Then, rho coefficients between those with and without ACEI were compared using Fisher’s
r-to-z transformation because Myers and Sirois [43] demonstrated that treating rho coefficients as if
they were Pearson’s coefficients was more robust than alternative approaches with respect to false
rejection of a true null hypothesis. A p-value below 0.05 was inferred significant.
Then, in order to check whether the effects of atorvastatin dosage on renal function were affected
by ACEI therapy, a generalized linear regression model was applied with a change in GFR as a
dependent variable. Since preliminary analyses did not allow the assumption of monotonic relations
between atorvastatin dose and the dependent variable across subgroups of the study subjects divided
on the basis of ACEI use, we entered 20-mg and 40-mg doses of atorvastatin as separate categorical
predictors. Then, effects of the both statin doses, ACEI use and interactions between ACEI usage and
each of the two statin doses were estimated. Regression coefficients for these factors are equivalent to
an effect on GFR in the patients exposed to a factor of interest with the reference to the patients without
this exposure. In order to adjust for potential continuous confounders, we planned to enter into the
model baseline characteristics for which the univariate p-value did not exceed 0.10. Additionally, to
control for time-dependent changes in LDL cholesterol and mean blood pressure, the analyses were
repeated with these covariates in the regression model. We also compared results of the two regression
models with and without inclusion of baseline GFR as a potential confounder. We used this approach
because, on the one hand, patients without ACEI exhibited significantly lower GFR due to a history of
adverse renal effects and, on the other hand, the adjustment for baseline levels of a variable may result
in a measurement error-dependent bias when searching for determinants of changes in this variable
over time [44,45].
5. Conclusions
Concomitant ACEI use appears to facilitate the ability of increasing atorvastatin doses to
beneficially modulate time-dependent changes in GFR in men with stable CAD.
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ACEI angiotensin-converting enzyme inhibitors
ANOVA analysis of variance
ARB angiotensin II type 1 receptor blockers
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